BRASILIA, Feb 5 (Reuters) - Brazilian pharmaceutical company
União Química expects health regulator Anvisa to approve
emergency use of Russia's Sputnik V vaccine against COVID-19
next week, its director for international business Rogerio Rosso
told Reuters on Friday.
Rosso said the company expects to draw up a contract by
Wednesday with the Health Ministry for an initial 10 million
imported doses based on a reference price of $10 per dose. He
said the ministry is also interested in buying the firm's entire
domestic production of Sputnik V, an estimated 8 million doses a
month from April, for Brazil's national immunization program.
(Reporting by Anthony Boadle
Editing by Brad Haynes)